Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O60487
UPID:
MPZL2_HUMAN
Alternative names:
Epithelial V-like antigen 1
Alternative UPACC:
O60487; A8K2R1
Background:
Myelin protein zero-like protein 2, also known as Epithelial V-like antigen 1, plays a crucial role in mediating homophilic cell-cell adhesion. This protein, encoded by the gene with the accession number O60487, is integral to the maintenance and function of various cellular structures.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 111, a condition characterized by early-onset, moderate to severe sensorineural deafness, Myelin protein zero-like protein 2's role in this genetic disorder underscores its potential as a target for therapeutic intervention. Understanding the role of Myelin protein zero-like protein 2 could open doors to potential therapeutic strategies.